GRID RNA Tumor Expression Profile analyzes genomic data points from a patient’s tumor and is available to physicians ordering Decipher Prostate Cancer Classifier tests

San Diego – GenomeDx Biosciences today announced that it has launched an expanded version of its Decipher GRID® Tumor RNA Expression Profile, a report generated for prostate tumors profiled with a Decipher Prostate Cancer Classifier test. The report features new markers and genomic signatures characterizing specific genomic attributes of the patients’ prostate cancer. The GRID Tumor RNA Expression Profile analyzes a multitude of molecular pathways and genomic signatures to enable physicians to better understand the unique attributes of the tumor.

The GRID Tumor RNA Expression Profile provides information to physicians, for Research Use Only, for every tumor profiled with a Decipher Prostate Cancer Classifier, a CLIA-validated genomic prognostic test for predicting tumor aggressiveness. GenomeDx hopes that the GRID Tumor RNA Expr